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Introduction 
Autoantibodies are the essential factors for several ctinical manifestations a sociated 
with a number of autoimmune diseases. The direct binding of certain atttoantibodies 
such as anti-erythrocyte and anti-platetet autoantibodies to their targets can cause au- 
toimmune cellular damage. Other autoantibodies such as anti-DNA autoantibodies 
can provoke tissue lesions as a result of their deposition in renal glomeruli and small 
vessels. However, because of the occasional lack of correlation between elevated se- 
rum levels of autoantibodies and clinical manifestations, it has long been suggested 
that only a subset of autoantibodies generated uring the course of autoimmune dis- 
eases is indeed pathogenic, and that the qualitative aspects of autoantibodies are im- 
portant for the pathogenesis of autoantibody-mediated cellular and tissue injuries. 
The structure of the Fab region defines the specificity and affinity with which au- 
toantibodies bind to self-antigen, and these characteristics are clearly of primary im- 
portance for pathogenic activities. In addition, the Fc region is also likely to play a 
critical role in autoantibody pathogenicity by activating IgG Fc-receptor(Fc,/R)-bear- 
ing effector cells, by activating the complement cascade and by inducing IgM multi- 
valency-dependent agglutination of target cells. Thus, the pathogenic potential of au- 
toantibodies i most straightforwardly attributable to the combined action of the self- 
antigen-binding properties of the Fab region and the effector functions associated 
with the Fc region of the different immunoglobulin (Ig) isotypes. Therefore, it is 
conceivable that a change of Ig isotype may result in a remarkable change in the 
pathogenic potential of autoantibodies, because Ig class switching can alter Fc-de- 
pendent effector functions and can be accompanied by concomitant changes in auto- 
antibody affinity (affinity maturation). Until recently this question has not been 
directly studied, because of the lack of suitable experimental models that easily 
reproduce some of the main pathological manifestations observed in autoimmune 
diseases. 
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For this reason, we have recently assessed the pathogenic activity of murine anti- 
erythrocyte monoclonal autoantibodies derived from autoimmune-prone NZB mice. 
This experimental system presents everal advantages. First, the binding of the anti- 
red blood cell (anti-RBC) autoantibodies in vivo, i.e., the presence of opsonized 
RBC, can be easily monitored by flow-cytometric analysis of circulating RBC after 
injection of anti-RBC autoantibodies into mice. Second, the pathogenic effect of the 
anti-RBC autoantibodies, i.e., the development of anemia, can be followed by a sim- 
ple measurement of hematocrit values. Finally, the histological analysis of spleen 
and liver can identify the pathogenic mechanisms of anemia, and its severity can be 
evaluated by analyzing the extent of erythrophagocytosis by Kupffer cells in the liv- 
er. In this article, we will discuss the molecular and cellular basis for pathogenic ac- 
tivities of anti-RBC autoantibodies with regard to their specificity and RBC-binding 
affinity, as well as the effector functions associated with the Fc region of the differ- 
ent Ig isotypes. 
Autoimmune hemolytic anemia in NZB mice 
NZB mice spontaneously develop autoimmune hemolytic anemia as a result of pro- 
duction of Coombs' autoantibodies reacting with their own RBC [26]. Although the 
molecular nature of the target autoantigens responsible for the induction of this auto- 
immune response has not been well characterized, the fact that autoantibodies luted 
from RBC of Coombs-positive NZB mice react only with mouse RBC but not with 
RBC from various other species [30] has suggested the importance of the specificity 
of these autoantibodies for their pathogenicity. A more detailed analysis of a panel of 
anti-RBC monoclonal antibodies (mAb) derived from NZB mice has shown that the 
pathogenic autoantibodies capable of inducing anemia recognize only species-specif- 
ic antigens on mouse RBC, while non-pathogenic autoantibodies cross-react with de- 
terminants present on RBC from many different species [9, 4811. The importance of 
the anti-mouse RBC specificity is further documented by the finding that, among 
five different IgM anti-RBC mAb, only the three pathogenic mAb (4C8, 1El0 and 
G8) are capable of inducing a marked hemagglutination, which is responsible for the 
development of anemia by this isotype. It may be that the surface density of antigen- 
ic determinants recognized by non-pathogenic lgM autoantibodies is too low to pro- 
mote agglutination of mouse RBC in vivo. Thus, differences in the distribution and 
the nature of target antigens likely account for the difference in the pathogenic activi- 
ties of these IgM anti-RBC mAb. 
The specificity of these autoantibodies reacting with exposed surface determi- 
nants of intact RBC is distinct from that of another category of erythrocyte autoanti- 
bodies which react with a cryptic surface antigen disclosed after proteolytic treat- 
ment with bromelain [30]. However, none of the autoantibodies specific for brome- 
lain-treated mouse RBC (BrMRBC) is able to induce anemia, excluding the possibil- 
ity that they play a primary role in the immune destruction of intact RBC, causing 
anemia. It is, however, possible that pathogenic anti-RBC autoantibodies may dam- 
age the RBC membrane sufficiently to expose the cryptic antigens, and consequently, 
anti-BrMRBC autoantibodies may additionally contribute to the hemolytic process 
[8]. Alternatively, these antibodies may represent physiological constituents of se- 
rum, serving as transporters of catabolic products, as proposed by Grabar [22], as 
they are detectable atsignificant levels in non-autoimmune mice. 
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High pathogenic potential of low-affinity anti-RBC autoantibodies promoting 
efficient Ig-isotype-dependent effector functions 
It has long been believed that the high-affinity binding of autoantibodies to self-anti- 
gens is critical for the expression of their pathogenic activities in vivo. This notion 
has been supported by the demonstration that the affinity maturation of autoantibod- 
ies resulting from somatic hypermutations i  the lg genes in association with IgM to 
IgG class switching coincides with progression of the clinical development of auto- 
immune diseases uch as systemic lupus erythematosus [24, 49, 57]. However, so- 
matic hypermutations do not always result in affinity maturation of autoantibodies, 
as observed in clonally related anti-IgG2a rheumatoid factors isolated from an auto- 
immune-prone MRL-Ipr/Ipr mouse [29]. More significantly, it has been shown that a 
low-affinity anti-IgG2a rheumatoid factor is able to induce lupus-like glomerulone- 
phritis and immune-complex-mediated vasculitis when provided with a cryoglobulin 
activity uniquely associated with murine IgG3 isotype [20]. Thus, it is possible that 
low-affinity anti-RBC autoantibodies could become highly pathogenic, if combined 
with appropriate Fc-dependent effector functions of a given lg isotype. 
In fact, the analysis of an IgG2a class-switch variant of 4C8 IgM anti-RBC mAb re- 
veals its high pathogenicity despite its low-affinity binding to mouse RBC (Table t). 
The low-affinity feature of the 4C8 mAb is documented by a markedly limited RBC- 
binding activity of the 4C8 IgG2a variant, 1,000 times lower than that of a high-af- 
finity 34-3C IgG2a mAb [19]. As expected, opsonized RBC is hardly detectable in
the circulating blood from mice injected with even 1 mg 4C8 IgG2a, in marked con- 
trast to the presence of bound antibodies on circulating RBC following the injection 
of as little as 1 lag 34-3C IgG2a mAb [I 9]. Nevertheless, to our surprise, the 4C8 
IgG2a variant with low binding affinity was abte to induce a severe anemia as a re- 
sult of Fc,tR-mediated erythrophagocytosis by hepatic Kupffer cells. This indicates 
that a remarkably efficient ability of the IgG2a isotype to interact with Fc~,R renders 
even low-affinity anti-RBC autoantibodies highly pathogenic. Most strikingly, the 
amount of the low-affinity 4C8 IgG2a variant required to induce anemia, despite a 
more than 1,000 times weaker RBC-binding activity, is comparable to that of the 
high-affinity 34-3C lgG2a mAb (Table 1). Thus, RBC-binding affinities of Coombs' 
Table 1. Pathogenic activities of low-affinity 4C8 Ig class-switch variants in comparison with those of 
high-affinity 34-3C and 105-2H mAb in autoimmune hemolytic anemia. The original isotype of the mAb 
isolated from NZB mice [48] is in roman type, while genetically produced switch variants are in italics. 
The anemic dose is the quantity of mAb required for inducing anemia, where hematocrit values below 
40% are considered as anemic 
mAb Affinity Isotype Anemic dose (pg) Pathogenicity 
4C8 Low IgM 50 lag High 
lgG2a 50 lag High 
lgG 1 1000 lag Intermediate 
IgG2b 5000 lag Low 
IgG3 - None 
34-3C High IgG2a 25 lag High 
lgGl 500 pg Intermediate 
t05-2H High IgG 1 500 vg Intermediate 
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autoantibodies apparently play a relatively minor role in the in vivo hemolytic activi- 
ties of the IgG2a isotype. 
It is, however, worth noting that when the pathogenic activities are compared in 
mice receiving higher doses of these two IgG2a anti-RBC mAb, the 34-3C mAb is 
clearly more pathogenic than the 4C8 IgG2a mAb [19]. This may be related in part 
to differential usage of two different classes of Fc~/R, high-affinity Fc'/RI and low-af- 
finity FcfRIII, involved in erythrophagocytosis. In fact, we have observed that both 
Fc'/RI and FcTRIII contribute to the development of anemia induced by a high dose 
(200 ~ag) of the 34-3C IgG2a mAb, while only the low-affinity FcyRIII is implicated 
in anemia provoked with the same amount of the 4C8 IgG2a mAb [18]. This sug- 
gests that the contribution of the high-affinity Fc~/RI to Kupffer-cell-mediated eryth- 
rophagocytosis is more dependent on the antigen-binding aff!nity of the IgG2a anti- 
RBC autoan6body. The usage of Fc'yRI by phagocytes i apparently limited in vivo 
because of the competition between IgG2a autoantibody bound to RBC and excess 
amounts of monomeric, tmbound lgG2a having a high-affinity interaction with 
Fc'tRI [60]. However, highly increased ensities of the 34-3C IgG2a bound on RBC 
could efficiently compete with circulating monomeric IgG2a for the binding to 
FctRI on phagocytes, thereby promoting erythrophagocytosis and hence accelerating 
the development of anemia. On the other hand, this is not the case for the binding to 
the low-affinity FcyRIII, which lacks significant affinity to monomeric IgG2a. In ad- 
dition, markedly opsonized RBC in mice receiving higher doses of the 34-3C mAb 
could efficientIy activate complement, hereby aggravating hemolytic anemia. In 
fact, this has been supported by our recent finding that the injection of 200 ~lg 34-3C 
IgG2a, but not 4C8 IgG2a, induces a significant anemia in mice lacking both phago- 
cytic Fc~/RI and FcyRIII (unpublished observation). Thus, an enhanced pathogenicity 
of the high-affinity 34-3C mAb at higher doses, as compared with the low-affinity 
4C8 IgG2a mAb, is likely due to the combined effect of a more efficient interaction 
with the high-affinity Fc~RI and a more efficient activation of the complement 
system. 
It should also be stressed that the pathogenic potential of the low-affinity 4C8 
IgG1 variant is almost comparable to that of the high-affinity 105-2H IgG1 and an 
lgG1 switch variant of the high-affinity 34-3C mAb (Table 1), all of which induce 
anemia through the activation of FcyR-dependent erythrophagocytosis [18, 31]. 
However, lgG2b and IgG3 class-switch variants of the 4C8 mAb are poorly patho- 
genic, because of limited interaction of these isotypes with Fc~/R (Tables 1, 2). This 
clearly indicates that the pathogenic activity of low-affinity IgG anti-RBC autoanti- 
bodies is dramatically enhanced, if combined with an appropriate Ig heavy-chain ef- 
fector function, namely the capacity to interact efficiently with FcTR involved in 
erythrophagocytosis. However, it is still possible that high-affinity anti-RBC autoan- 
tibodies of IgG2b and IgG3 isotypes could become more pathogenic, owing to their 
enhanced interaction with Fo/R and/or activation of complement as a result of a 
markedly increased opsonization, as compared with their low-affinity counterparts. 
In addition to the remarkable contribution of the lgG Fc region to the pathogenic 
activities of the low-affinity 4C8 IgG2a variant, it is worth noting that the low-affini- 
ty 4C8 IgM isotype is also highly pathogenic to an extent comparable to that of its 
IgG2a variant and the high-affinity 34-3C IgG2a mAb (Table 1). The strong patho- 
genic activity of the 4C8 IgM isotype is dependent on its pentameric form, since it 
promotes a high-avidity binding, which is more than 1,000 times stronger than that 
of its IgG2a variant and comparable to that of the 34-3C IgG2a mAb [19], and induc- 
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es the agglutination of RBC in vivo [48]. Consequently, the IgM isotype of the 4C8 
mAb induces a different form of anemia, resulting from massive agglutination of 
RBC in spleen and liver, which does not involve Fc•R-mediated phagocytosis and 
complement activation [12, 48]. The importance of the pentameric form of IgM for 
the in vivo agglutination of RBC is further supported by the finding that an IgG3 
variant of the 4C8 mAb, which is unable to mediate Fc'lR-dependent erythrophago- 
cytosis, fails to induce agglutination of RBC in vivo [18]. 
The demonstration f the high pathogenic potency of low-affinity autoantibodies 
suggests that the affinity maturation of autoantibodies may not necessarily be a criti- 
cal process for the generation of autoantibodies with immunopathological onse- 
quences. It has also been shown that a tow-affinity anti-IgG2a rheumatoid factor of 
IgG3 isotype is able to induce lupus-like glomerulonephritis and immune-complex- 
mediated skin vasculitis, owing to the IgG3-dependent cryoglobulin activity [20]. 
These results provide new insight into the cellular basis of the generation of patho- 
genic autoantibodies. It has already been shown that a fraction of B cells expressing 
the low-affinity 4C8 autoantibody can escape clonal deletion in the bone marrow and 
can be activated to produce pathogenic autoantibodies in the periphery, as a result of 
nonspecific B cell activation [33, 34]. These autoantibodies may even be switched to 
IgG classes under certain conditions, possibly through the action of cytokines and in- 
dependently of the presence of autoantigen-specific T helper cells, as in the case of 
T-independent type II immune responses [50]. Genetic abnormalities present in cer- 
tain autoimmune-prone mice may favor the switching of IgM to IgG isotypes, as 
shown by a spontaneous class switch from IgM to IgG2a autoantibody in B cells de- 
rived from lupus-prone (NZB • NZW)FI mice in the absence of functional CD4 + T 
helper cells [42, 43]. It has been hypothesized that autoreactive B cells can be gener- 
ated as a result of somatic hypermutations i  the germinal centers during immune re- 
sponses against environmental ntigens, and that such B cells may persist, if they are 
defective in the process of apoptosis, which is likely to be one of the genetic defects 
present in autoimmune-prone mice [13, 58]. This suggests that pathogenic autoanti- 
bodies can be generated at least partly by a mechanism that is independent of the ac- 
tivation of autoreactive B cells by autoreactive T helper ceils and self-antigens. 
Dif[erential contributions of high-affinity FcyRl and low-affinity FcyRlI1 
to IgG-iso~pe-dependent a ti-RBC pathogenicity 
An initial analysis of pathogenic anti-RBC mAb bearing different Ig isotypes has 
shown that complement activation plays a minimal role in the development of ane- 
mia [48]. In contrast, Fc'~R-mediated rythrophagocytosis by IgG anti-RBC mAb and 
splenic and hepatic sequestration f RBC agglutinated by IgM anti-RBC mAb have 
been recognized as the major pathogenic mechanisms responsible for autoimmune 
hemolytic anemia in mice [12, 31, 48]. Murine phagocytic cells express two different 
classes of phagocytic FcyR: the high-affinity FcyRI and the low-affinity Fc,/RIII (for 
reviews, see [27, 37, 39]). The high-affinity Fc?RI is capable of binding monomeric 
IgG2a [60], while the low-affinity Fc'tRIII binds polymeric forms of different IgG 
isotypes except IgG3 [62]. Both FmlR are hetero-oligomeric complexes, in which the 
respective ligand-binding c~ chains are associated with the common "~ chain, which is 
critical for the assembly and cell-surface xpression of functional Fc'fRI and FcyRIII. 
The FcR v chain carries a cytoplasmic ITAM (immunoreceptor y osine-based acti- 
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'lhble 2. Pathogenic activities of the 4C8 Ig class-switch variants, respective contributions of Fc~/RI and 
FcyRIIl to the development of 4C8-induced anemia, nd their relative affinities to polymeric forms of the 
four IgG isotypes. The relative pathogenic a tivity of individual Ig isotypes of the 4C8 anti-RBC mAb is 
expressed asa percentage of the capacity of the 4C8 IgM mAb to induce anemia (Table I). The relative in 
vivo affinity of Fc'/RI and FcyRIII to polymeric forms of the four different IgG isotypes i arbitrarily grad- 
ed on the basis of in vivo evidence for erythrophagocytosis by Kupffer cells in the liver of different Fc,/R- 
deficient mice 
Isotype Pathogenicity (%) Fc,/R contribution Affinity of 
FcTRI FcyRIII 
IgM 1 O0 - - - 
IgG 1 5 Fc,/RIII - ++ 
IgG2a 100 Fc~RIII>FwRI ++ +++ 
IgG2b 1 Fc'/RIII/Fc'fRI + + 
IgG3 0 - - - 
vation motif) sequence required for the recruitment and activation of the Src and Syk 
family of protein tyrosine kinases [15]. Thus, the FcR y chain is an essential compo- 
nent for the triggering of various effector functions of both Fc,/RI and Fc'/RIII, in- 
cluding phagocytosis by macrophages, degranulation by mast cells and antibody-de- 
pendent cell-mediated cytotoxicity by natural killer cells [54]. 
The in vivo pathogenicity of anti-RBC autoantibodies of different IgG isotypes 
may be critically dependent on the relative affinities of FcyRI and FcyRIII to the 
polymeric form of each IgG isotype, in view of the major role of Fc,/R-mediated 
erythrophagocytosis in the pathogenesis of autoimmune hemolytic anemia [12, 31, 
48]. This question has been recently addressed by assessing the pathogenic potency 
of four different IgG class-switch variants (IgG1, IgG2a, IgG2b and lgG3) of the 
low-affinity 4C8 anti-RBC mAb in relation to their utilization of the two classes of 
phagocytic Fc,/R [18]. Our analysis has demonstrated that the four IgG isotypes of 
this autoantibody display striking differences in pathogenicity. The IgG2a isotype ex- 
hibits the highest pathogenicity, approximately 20- and 100-fold more potent than 
that of its IgG1 and IgG2b variants respectively, while the IgG3 valiant is not patho- 
genic at all (Tables 1, 2). These differences are apparently determined by the capaci- 
ty of individual IgG isotypes to interact in vivo with FcyRI and FcyRIII. In fact, the 
IgG2a isotype interacts most efficiently with both FcyRI and FcTRIII, the IgG1 iso- 
type binds only with the low-affinity Fc,/RIII, and the IgG2b isotype apparently in- 
teracts only weakly with both receptors (Table 2). In contrast, the IgG3 isotype dis- 
plays little interaction with these phagocytic FcyR. 
The complete dependence of the 4C8 IgGl-mediated erythrophagocytosis on
FcyRIII is consistent with the results obtained with the 105-2H IgG1 anti-RBC mAb 
[31] and 34-3C IgG1 switch variant (unpublished observation). On the basis of in 
vitro studies using macrophages or transfected cell lines, it has been proposed that 
Fc~/RIII has a comparable affinity to IgGl,  IgG2a and IgG2b, but little affinity to 
IgG3 [23, 62]. However, our in vivo analysis in different Fc,/,R-deficient mice has 
clearly demonstrated marked differences in the relative affinity of FcyRIII to these 
three IgG isotypes; highest for IgG2a, intermediate for IgG1 and lowest for IgG2b, 
which directly reflects the different pathogenicity of these different IgG isotypes (Ta- 
ble 2). 
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It is striking to observe that mice lacking Fc?RIII are totally resistant to the patho- 
genic effect of lower doses (50-200 ~tg) of the 4C8 IgG2a variant, while FcTRI addi- 
tionally contributes to IgG2a-dependent erythrophagocytosis only when higher doses 
(above 1 mg) of the anti-RBC mAb are injected [18]. This indicates that FcyRllI 
plays a major role in the 4C8-IgG2a-induced anemia, which is also the case for ane- 
mia induced by the 34-3C IgG2a mAb. This demonstration is somehow unexpected, 
since it has been thought hat IgG2a immune complexes preferentially interact with 
FcyRI because of its high-binding affinity to the IgG2a isotype [60]. However, as 
discussed above, a limited utilization of FcyRI for phagocytosis of IgG2a-opsonized 
RBC, due to competition with excess amounts of circulating monomeric IgG2a, 
cotdd explain this observation. In fact, our recent demonstration f an enhanced utili- 
zation of FcyRI in IgG2a-dependent erythrophagocytosis in Ig-deficient mice con- 
firms this idea (manuscript in preparation). 
It has long been believed that the IgG2b isotype is unable to interact with the 
high-affinity FcyRI [28]. However, studies with the 4C8 IgG2b variant reveal that 
FcyRI apparently has a significant affinity to lgG2b immune complexes, though 
much lower than that to IgG2a immune complexes [18]. This conclusion is drawn 
from the observation that 4C8-IgG2b-dependent erythrophagocytosis by Kupffer 
cells is little affected by the absence of either FcyRI or FcyRIII, but completely pro- 
tected in FcRy-deficient mice lacking both FcyRl and FcyRllI, indicating a signifi- 
cant contribution of FcyRI as well as FcyRIlI to IgG2b-induced autoimmune hemo- 
lytic anemia (Table 2). Notably similar results are obtained with in vitro studies us- 
ing peritoneal macrophages i olated from mice deficient in FcyRI and/or FcyRIII. 
Therefore, the lack of detectable binding of IgG2b-opsonized RBC to FcyRI in previ- 
ous studies may be in part related to the fact that these results were obtained by using 
COS cells transfected with FcyRIct cDNA, thereby expressing FcyRl c~ chains but 
not ,r chains [17, 28]. Thus, the "FcyRI" expressed on those transfected celIs do not 
appear to behave like the native receptors, the expression of which on phagocytic ef- 
lector cells is totally dependent on FcR y chains [54]. In fact, the affinity of the 
"FcyRI" expressed on COS cells is 2- to 5-fold lower than that of the native FcyRI 
[32], which would explain the lack of binding of IgG2b-opsonized RBC to the 
"FcyRI", because of a weak binding affinity of FcyRI to IgG2b immune complexes. 
It has been controversial whether there exists any receptor for murine IgG3 iso- 
type. Diamond and Yelton proposed some time ago that a new, previously unidenti- 
fied IgG3-specific phagocytic FcyR might be expressed on macrophages [16]. More 
recently, following work using bone-marrow-derived macrophages from FcyRI-defi- 
cient mice, FcyRI has been claimed to be the sole receptor for the lgG3 isotype [21]. 
However, the complete absence of erythrophagocytosis by Kupffer ceils in mice, 
even after the implantation of 4C8-IgG3-secreting cells, argues against any signifi- 
cant affinity of both FcyRI and FcyRIII to murine IgG3 isotype in vivo [18]. One 
should nevertheless consider that RBC are very poorly opsonized by the 4C8 IgG3 
variant, and that the affinity, if any, of FcyRI for the IgG3 isotype is apparently lower 
than that for the IgG2a isotype [21]. Therefore, one cannot exclude the possibility 
that the interaction of Fc~RI with a limited amount of the 4C8 IgG3 mAb present on 
RBC can be readily interfered with by an excess of circulating monomeric IgG2a. 
However, the finding that a high-affinity IgG3 mAb against cryptococcal capsular 
polysaccharide also fails to provoke phagocytosis through both FcyRI and FcyRIII in 
vitro and in vivo [63] strongly argues against his possibility, further supporting the 
lack of interaction of FcyRI and FcyRIII with the IgG3 isotype. 
440 S. Izui et al. 
Lack of contribution of the inhibitory FcyRIIB to autoimmune hemolytic anemia 
Murine phagocytic effector cells express an additional Fc,/R, FcyRIIB, which is a 
single ct chain receptor, in which the extracellular domain is highly homologous with 
its aetivatory counterpart, while its cytoplasmic domain contains the inhibitory ITIM 
(immunoreceptor y osine-based inhibition motif) sequence [2]. Upon coligation of 
the inhibitory Fc,/R to an ITAM containing activatory FcTR, cell activation is inhibit- 
ed by the recruitment of an inositol-polyphosphate phosphatase, SHIP, which medi- 
ates the inhibition of calcium flux [35]. Murine FcyRIIB exist in two major isoforms, 
Fc,/RIIB1 and Fc,/RIIB2 [40]. The B I isoform is not efficiently internalized upon 
binding of IgG immune complexes, because of the presence of a 47-amino-acid in- 
sertion in the cytoplasmic region, but mediates inhibition of B cell activation after 
coligation with the B cell antigen receptor (BCR) [2]. In contrast, the FcyRIIB2 iso- 
form is capable of promoting the endocytosis of IgG immune complexes, thereby fa- 
cilitating antigen processing and presentation by macrophages [2]. Nevertheless, the 
complete dependence of erythrophagocytosis on FcyRI and/or Fc,/RIII, as observed 
in studies with different 4C8 IgG class-switch variants, clearly indicates a lack of 
phagocytosis-inducing capacity of Fc,/RIIB [ 18]. 
It has been demonstrated that Fc'/RIIB-deficient mice exhibit higher humoral, 
anaphylactic and inflammatory immune responses, which underlines the importance 
of Fc'IRIIB for the negative regulation of BCR-, FctRI- and Fc,fRIII-dependent ef- 
fector functions in vivo [11, 46, 55, 59]. However, we have recently shown that 
FcyRIIB is unable to down-regulate FcyRI- and FcyRIII-mediated phagocytosis of 
RBC opsonized with 34-3C IgG2a (unpublished observation) or 105-2H IgG1 anti- 
RBC mAb in vivo [46]. In this regard, it is somehow unexpected that the develop- 
ment of immune thrombocytopenia induced by an IgG2a anti-platetet mAb is appar- 
ently down-regulated byFcyRIIB [44]. This may raise the possibility that the devel- 
opment of thrombocytopenia following the injection of IgG2a anti-platetet autoanti- 
bodies may be mediated not only by FcyR-mediated phagocytosis but also by anoth- 
er mechanism as a consequence of Fc'/R-triggered activation of macrophages. This 
latter process may be efficiently counter-regulated by the co-engagement of
Fc'~RIIB, while it is not relevant o the development of autoimmune hemolytic ane- 
mia. 
Possible role of complement in autoimmune hemolytic anemia 
The complement components interact most efficiently with mouse tgM immune 
complexes and to a lesser extent with IgG2a immune complexes, which trigger the 
classical pathway of complement activation by binding of Clq. Therefore, it is 
somehow surprising to see that none of the anti-RBC mAb, even of the IgM iso- 
type, is able to induce hemolysis of mouse RBC in vitro in the presence of comple- 
ment from any species [48]. In addition, the development of anemia induced by 
4C8 IgM and 34-3C IgG2a mAb is hardly affected in C5-deficient DBA/2 mice as 
well as in BALB/c mice depleted of C3 by the treatment with cobra venom factor 
[31, 48]. These data thus indicate limited, if any, activation of complement by anti- 
RBC autoantibodies in mice. However, non-complement-fixing IgM antibodies 
with diverse specificities have been described [36, 61], and the structure of the an- 
tigen appears to influence the capacity of IgM antibodies to fix and/or activate 
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complement [14]. Therefore, it is possible that the limited activation of comple- 
ment by anti-mouse RBC monoclonal autoantibodies may be related to the particu- 
lar structure of the target autoantigen. In addition, it is known that the reaction of 
complement-binding antibodies with RBC does not always lead to complement ac- 
tivation. This is due to the activity of a number of complement-inhibitory p oteins 
present on RBC membranes, and these regulatory proteins likely play an important 
role in preventing excessive damage to autologous cells. This would explain why 
the development of anemia caused by polyclonal rabbit IgG anti-mouse RBC anti- 
bodies, which are expected to activate complement, is hardly affected in mice ge- 
netically deficient in C3, but almost completely prevented in mice lacking both 
FcyRl and Fc~RIII [51 ]. 
These results, however, cannot totally exclude a possible role of C4 in autoim- 
mune hemolytic anemia, since the C4b fragment is recognized by complement recep- 
tors, which stimulate phagocytosis (for reviews, see [1, 6]). In addition, in vivo 
clearance xperiments of RBC sensitized with polyclonal rabbit IgG anti-RBC anti- 
bodies in C4-deficient and control guinea pigs have shown that erythrophagocytosis 
can be mediated by the synergistic ooperation of Fc~,R and complement receptors 
expressed on Kupffer ceils [47]. Such a synergistic ooperation has also been dem- 
onstrated in a study using human peripheral blood monocytes in vitro [7]. This 
mechanism could be operative under certain conditions, depending on the extent of 
opsonization and the IgG isotypes of anti-RBC autoantibodies. In fact, our recent re- 
sults suggest an additional rote of complement in the accelerated development of
anemia in mice receiving higher doses of the high-affinity 34-3C IgG2a mAb (manu- 
script in preparation). Clearly, more extensive analysis in C3- and C4-deficient mice 
in relation to the IgG isotypes of anti-RBC autoantibodies, their RBC-binding affini- 
ties and the extent of RBC opsonization could help to define more precisely the role 
of complement in the development of autoimmune hemolytic anemia. 
In addition to autoimmune hemolytic anemia, the study with an IgG2a anti-plate- 
let monoclonal autoantibody has also shown a minimal role of complement in im- 
mune elimination of platelets [51]. Moreover, it has been reported that C3- and C4- 
deficient mice respond normally to the presence of pathogenic immune complexes 
by generating the Arthus reaction [51], in which Fc~/R-dependent activation of mast 
cells appears to be the major pathogenic mechanism [52]. In contrast, recent studies 
on such complement-deficient mice have clearly shown that complement is essential 
in innate immunity to bacterial pathogens, in which the interaction of natural IgM 
antibodies with bacteria pparently plays a critical role in the activation of the classi- 
cal pathway of complement (for review, see [38]). On the basis of these findings, 
Ravetch and Clynes have proposed the following hypothesis: complement activation 
is essential in protection through natural IgM antibodies during innate immune re- 
sponses, but not in immune-complex-triggered inflammation, while Fc~,R relay the 
action of IgG antibodies to effector cells and initiate the inflammatory cascade, 
thereby playing the dominant role in autoantibody-triggered autoimmune diseases. 
However, more recent studies have shown that complement is indeed required for the 
full-blown expression of immune-complex-mediated inflammatory reactions in sev- 
eral experimental models including the Arthus reaction, immune complex alveolitis 
and anti-glomerular basement membrane nephritis [4, 5, 25, 56]. As discussed above, 
more extensive analysis in complement- or complement-receptor-deficient mice is 
awaited to elucidate what role complement really plays in autoantibody-triggered 
autoimmune cellular and tissue injuries. 
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Concluding remarks 
The use of four different anti-RBC IgG switch variants bearing identical variable re- 
gions has provided a unique opportunity to define the pathogenic potency of individ- 
ual murine IgG isotypes in relation to the respective roles of high-affinity FcTRI and 
low-affinity FcyRI[I. Given the role of Fm/R in phagocytosis, cellular cytotoxicity 
and release of inflammatory mediators by different ypes of inflammatory effector 
cells, it is important to understand the respective roles of the two different classes of 
activatory FcyR, which interact differentially with individual lgG isotypes. Striking- 
ly, the capacity of each IgG isotype to interact with the low-affinity Fcs, RII1 is the 
critical factor determining the pathogenic potency of individual IgG isotypes, while 
the high-affinity FcyRI apparently plays a relatively limited role, probably because 
of the competition with circulating monomeric IgG2a. 
The demonstration f the highest pathogenic potency of the IgG2a isotype high- 
lights the importance of the regulation of [gG isotype responses in both autoanti- 
body-mediated diseases and immune-complex-mediated inflammatory disorders. A 
recent study has shown that Fc~/R-mediated inflammatory esponses play an impor- 
tant role in the pathogenesis of lupus-like glomerulonephritis [10], supporting the 
possibility of a higher nephritogenic potential for autoantibodies of the IgG2a iso- 
type. Although anti-RBC autoantibodies of the lgG3 isotype appear to be less patho- 
genic, nephritogenic activities of IgG3 autoantibodies have also been well estab- 
lished, on the basis of a cryoglobulin activity uniquely associated with the IgG3 
heavy-chain constant region [20, 41 ]. These findings are consistent with the observa- 
tion that the progression of routine lupus-like autoimmune syndrome is con'elated 
with the relative dominance of Th 1 autoimmune r sponses promoting the production 
of IgG2a and IgG3 autoantibodies [3, z~5, 53]. Clearly, further studies on the patho- 
genic role of autoantibodies of different Ig isotypes in relation with the Th subset re- 
sponse would help establish new strategies for the development of therapeutic ap- 
proaches in autoantibody-mediated utoimmune diseases. 
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